Melissa Bradford-Klug

Melissa Bradford-Klug was previously chief business officer at Keryx and is responsible for business development, corporate strategy and alliance management. She joined Keryx in January 2017 bringing to the company more than 17 years of strategic planning, licensing and business development expertise in the life sciences industry. Prior to Keryx, Ms. Bradford-Klug was at AMAG Pharmaceuticals, from 2014 to 2016, where she served as senior vice president of business development and strategy and executed multiple transformational acquisitions that led to AMAG’s portfolio expansion into maternal and women’s health. Prior to AMAG, she spent approximately 10 years at Mallinckrodt where she was vice president, business development and licensing. During her tenure at Mallinckrodt, she completed several transformational acquisitions and divestitures and was instrumental in the spinout of Mallinckrodt from Covidien. Earlier in her career, she held leadership roles with Baxter International and Eli Lilly and Company. Ms. Bradford-Klug received an M.B.A. in Finance from DePaul University and a B.S. in chemistry from Maryville University.